1. Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma 
Sergio Bracarda, Alain Ravaud, Marino Chiodi 
European Urology Supplements 
Volume 8, Issue 10, Pages (November 2009)
DOI: /j.eursup
Copyright © 2009 European Association of Urology Terms and Conditions

2. Fig. 1
(a) Lung computed tomography (CT) scan and (b) abdominal CT scan of a patient with metastatic renal cell carcinoma prior to treatment with everolimus; (c) lung CT scan and (d) abdominal CT scan of patient 16 mo after initiation of everolimus treatment. Arrows indicate metastases.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

3. Fig. 2
(a) Computed tomography scan showing mediastinal lymph node metastases; (b) evidence of significant reduction after 8 mo of treatment with open-label everolimus.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

4. Fig. 3
Summary of responses to treatment over time in two patients with metastatic renal cell carcinoma. Approximate timelines are given.
IFN-α=interferon alfa; VEGF=vascular endothelial growth factor.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions